Our Editorial Team

Affiliations

Castle Connolly
Our Editorial Team

Thomas Urban Marron, MD, PhD

Medical Reviewer

Thomas Marron, MD, PhD, is the assistant director of early phase and immunotherapy clinical trials at the Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai in New York City, as well as an assistant professor of medicine in the Icahn School of Medicine. He is a physician scientist working to translate findings from the lab into patient care and treatment. His clinical focus is on early phase clinical trials of cancer vaccines and new immunotherapy combination treatments.

Dr. Marron received his bachelor's degree in human biology from the University of Virginia in Charlottesville...

Affiliations

Castle Connolly

Expertise

Medical oncology, immunology, immunotherapy

Board Certifications and Training

  • Board-Certified in Internal Medicine and Medical Oncology

Education

  • Bachelor of Arts (BA) in Human Biology, University of Virginia
  • Doctor of Philosophy (PhD) in Biomedical Science and Immunology, Icahn School of Medicine
  • Doctor of Medicine (MD), Icahn School of Medicine

Awards and Accreditation

  • Castle Connolly Rising Star
  • Member, Society for the Immunotherapy of Cancer (SITC)
  • Member, American Society of Clinical Oncology (ASCO)
  • Member, American Association of Cancer Research (AACR)
  • Member, International Association for the Study of Lung Cancer

Press Coverage

Research:

Marron, T. U., Gunasekaran, G., Tabrizian, P., Kim, E., Fiel, M. I., Ward, S., ... & Merad, M. (2021). Abstract CT182: Neoadjuvant cemiplimab demonstrates complete pathological responses in hepatocellular carcinoma. Cancer Research, 81(13_Supplement), CT182-CT182.

Sharma, R., Pillai, A., Marron, T. U., Fessas, P., Saeed, A., Jun, T., ... & Pinato, D. J. (2022). Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatology Communications.

Jun, T., Dharmapuri, S., Marron, T. U., Sung, M. W., & Ang, C. (2020). Effect of baseline medications on response to immunotherapy in hepatocellular carcinoma.

Marron, T. U., Binder, A., Bhardwaj, N., Kim-Schulze, S., Keler, T., Davis, T., ... & Brody, J. (2015). In situ vaccine for low-grade lymphoma: Combination of intratumoral Flt3L and poly-ICLC with low-Dose radiotherapy.

Lutzky, J., Marron, T. U., Powell, S. F., Johnson, D. H., Patel, M., El-Khoueiry, A. B., ... & Sznol, M. (2022). Optimization of Voyager V1 (VV1) oncolytic virus systemic delivery in combination with cemiplimab and ipilimumab in patients with melanoma and non–small cell lung cancer (NSCLC).

Contact Thomas

See More